Instrument Inactif

Communiqués Essex Bio-Technology Limited Deutsche Boerse AG

Actions

EB51

KYG312371035

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%	18/03	AQ
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%	16/08/23	AQ
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed	26/07/23	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement	14/04/23	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore	14/04/23	AQ
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China	11/04/23	AQ
Essex Bio-Technology Announces 2022 Annual Financial Results	08/03/23	AQ
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration	22/02/23	AQ
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases	10/02/23	AQ
Essex Biotechnology Secures Exclusive Global Rights	14/10/22	AQ
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech	13/10/22	AQ
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"	16/08/22	AQ
Essex Bio-Technology Announces 2021 Financial Results	22/03/22	AQ
Essex Bio Technology : NEXT DAY DISCLOSURE RETURN	17/08/21	PU
Essex Bio Technology : 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	07/05/21	PU
Essex Bio Technology : VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION	20/04/21	PU
Essex Bio Technology : INSIDE INFORMATION APPROVAL TO COMMERCIALISE PRESERVATIVE-FREE UNIT-DOSE MOXIFLOXACIN HYDROCHLORIDE EYE DROPS IN THE PRC	07/04/21	PU
Essex Bio Technology : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 12 MAY 2021 (or any adjournment thereof)	25/03/21	PU
Essex Bio Technology : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	25/03/21	PU
Essex Bio Technology : VOLUNTARY ANNOUNCEMENT FURTHER UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION	19/03/21	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Essex Bio-Technology Limited Deutsche Boerse AG

Actions

EB51

KYG312371035

Communiqués

Filtres